Live tape
Top 8, mentions 7d10,311TSLA2,210 mentions▲ +0.05GOOGL1,427 mentions▲ +0.04CRWV1,396 mentions▲ +0.03SPCX1,283 mentions▲ +0.06NVDA1,170 mentions▲ +0.07QQQ1,109 mentions▲ +0.04NBIS906 mentions▲ +0.06META810 mentions▲ +0.05

Equity · Healthcare

ASND

NASDAQ

Ascendis Pharma A/S (ASND)

$230 +2.22% vs prior close Finazon · prior-day close, indicative (IEX-derived, not the official close) · Oct 19, 2026
Price · Chart
63 sessions
$280 $220 22 Jul 19 Oct

The line runs $252 on 22 July through $230 on 19 October, on a scale from $220 to $280. Days the market did not trade hold the previous close, flat.

Track this symbol on TradingView TradingView chart · our licensed closes: 63 sessions, 22 Jul – 19 Oct 2026
52-week range $196 – $277
Avg volume 54.0K

as of Oct 19, 2026

Ascendis Pharma A/S (ASND) insider trades

SEC Form 4 · last 90 days · newest reported trade 8 Sep 2026

In the 90 days to 21 Oct 2026, Ascendis Pharma A/S insiders reported 2 open-market sales and 1 purchase (SEC Form 4).

Open-market buys 1
Open-market sells 2
Net sold $380K
Non-trade filings 1
Date Insider Type Shares Value
08 Sep 2026 Bodenhoff Mads SVP & PAO Sell 3,000 $811K
02 Sep 2026 HOLTUG LARS Director Sell 236 $62K
14 Aug 2026 BIENAIME JEAN JACQUES Director Buy 2,000 $493K

Compensation mechanics Share grants, option exercises, tax withholding and transfers. They reach the same Form 4 as a trade, but they are not the insider buying or selling on the open market, so no purchase or sale value applies to them.

Date Insider Type Shares Value
08 Sep 2026 Bodenhoff Mads SVP & PAO Option exercise 3,000 $330K

Ascendis Pharma A/S (ASND) institutional holders (13F)

SEC Form 13F SEC EDGAR

8 of the 45 institutional funds we track reported a Ascendis Pharma A/S position for the quarter ended 30 Jun 2026 — a combined $248.4M; the latest of those filings landed 02 Sep 2026.

Fund Action Shares Value
Two Sigma Investments New position 305,803 $81.6M
Millennium Management New position 266,708 $71.1M
Citadel Advisors New position 137,889 $36.8M
Renaissance Technologies New position 119,699 $31.9M
Balyasny Asset Management New position 31,023 $8.3M
D. E. Shaw & Co. New position 30,883 $8.2M
Marshall Wace New position 22,503 $6.0M
Tudor Investment Corp New position 16,625 $4.4M
AQR Capital Management Exited
D. E. Shaw & Co. Exited

Ascendis Pharma A/S (ASND) fails-to-deliver

SEC CNS data SEC

On 28 Sep 2026, 1,158 shares of Ascendis Pharma A/S failed to deliver (about $261K) — the latest of 2 consecutive trading days with recorded fails.

Settlement date Shares failed Notional % of shares out
28 Sep 2026 1,158 $261K 0.002%
25 Sep 2026 1,158 $267K 0.002%
23 Sep 2026 46 $11K <0.001%
21 Sep 2026 77 $18K <0.001%

Congressional trades in Ascendis Pharma A/S (ASND)

STOCK Act disclosures House disclosures

The most recent congressional trade disclosed in Ascendis Pharma A/S is a purchase by Gary J. Palmer (house, AL), dated 12 Jul 2018.

Date Member Type Amount
12 Jul 2018 filed 29 Sep 2018 Gary J. Palmer house · Republican–AL Purchase $1K–$15K

Ascendis Pharma A/S (ASND): frequently asked questions

From live data

Have Ascendis Pharma A/S insiders bought or sold shares recently?

In the 90 days to 21 Oct 2026, Ascendis Pharma A/S insiders reported 2 open-market sales and 1 purchase (SEC Form 4). A further 1 filing was a grant, award, gift or exercise rather than an open-market trade.

How many institutions hold Ascendis Pharma A/S?

8 of the 45 institutional funds we track reported a Ascendis Pharma A/S position for the quarter ended 30 Jun 2026, per SEC Form 13F filings.

Has Ascendis Pharma A/S had fails-to-deliver recently?

Yes. The most recent SEC fails-to-deliver record for Ascendis Pharma A/S is dated 28 Sep 2026, when 1,158 shares failed to deliver.

What exchange is Ascendis Pharma A/S listed on?

Ascendis Pharma A/S trades on NASDAQ under the ticker ASND.

Answers are generated from the live figures on this page — Reddit crowd data, SEC filings and open company records — and update as the data does.

Sources

  1. Finazonprior-day close, indicative (IEX-derived, not the official close), most closes dollar-rounded at the source
  2. TradingViewthe price chart widget, drawn by TradingView from their own data
  3. SEC EDGARSEC EDGAR 13F filings
  4. SECSEC fails-to-deliver (CNS) data
  5. House disclosuresU.S. House of Representatives financial disclosures